Author

Rinse K. Weersma

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

Rinse K. Weersma  et al.

SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE
SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE

Rinse K. Weersma  et al.

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

LONGITUDINAL CHANGES IN THE GUT MICROBIOME IN RESPONSE TO IMMUNE CHECKPOINT BLOCKADE
LONGITUDINAL CHANGES IN THE GUT MICROBIOME IN RESPONSE TO IMMUNE CHECKPOINT BLOCKADE

Rinse K. Weersma  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

Rinse K. Weersma  et al.

GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

CHARACTERISING THE SMALL INTESTINE MICROBIOTA USING INDIVIDUALS WITH AN ILEOSTOMY OR ILEOANAL POUCH IN THE CONTEXT OF IBD
CHARACTERISING THE SMALL INTESTINE MICROBIOTA USING INDIVIDUALS WITH AN ILEOSTOMY OR ILEOANAL POUCH IN THE CONTEXT OF IBD

Rinse K. Weersma  et al.

INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

THE GUT MICROBIOME OF HEALTHY SIBLINGS OF INFLAMMATORY BOWEL DISEASE (IBD) TWINS DISPLAYS IBD SIGNATURES
THE GUT MICROBIOME OF HEALTHY SIBLINGS OF INFLAMMATORY BOWEL DISEASE (IBD) TWINS DISPLAYS IBD SIGNATURES

Rinse K. Weersma  et al.

DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

HIGH-DIMENSIONAL SINGLE-CELL ANALYSIS IDENTIFIES CELLULAR SIGNATURES ASSOCIATED WITH RESPONSE TO VEDOLIZUMAB THERAPY IN ULCERATIVE COLITIS
HIGH-DIMENSIONAL SINGLE-CELL ANALYSIS IDENTIFIES CELLULAR SIGNATURES ASSOCIATED WITH RESPONSE TO VEDOLIZUMAB THERAPY IN ULCERATIVE COLITIS

Rinse K. Weersma  et al.

DEVELOPMENT OF PRECANCEROUS COLONIC LESIONS IS ASSOCIATED WITH GUT MICROBIOTA IN THE DUTCH MICROBIOME PROJECT COHORT STUDY
DEVELOPMENT OF PRECANCEROUS COLONIC LESIONS IS ASSOCIATED WITH GUT MICROBIOTA IN THE DUTCH MICROBIOME PROJECT COHORT STUDY

Rinse K. Weersma  et al.

GUT MICROBIOME COMPOSITION AND FUNCTION ARE LINKED TO THE DEVELOPMENT OF (PRE)CANCEROUS COLONIC LESIONS IN A PROSPECTIVE FOLLOW UP STUDY OF THE DUTCH MICROBIOME PROJECT
GUT MICROBIOME COMPOSITION AND FUNCTION ARE LINKED TO THE DEVELOPMENT OF (PRE)CANCEROUS COLONIC LESIONS IN A PROSPECTIVE FOLLOW UP STUDY OF THE DUTCH MICROBIOME PROJECT

Rinse K. Weersma  et al.

ER STRESS AS A RHEOSTAT OF LIPID-INDUCED METABOLIC ENTERITIS IN CROHN’S DISEASE
ER STRESS AS A RHEOSTAT OF LIPID-INDUCED METABOLIC ENTERITIS IN CROHN’S DISEASE

Rinse K. Weersma  et al.

LIPID PEROXIDATION FUELS INTESTINAL INFLAMMATION VIA A TLR2-JNK AXIS
LIPID PEROXIDATION FUELS INTESTINAL INFLAMMATION VIA A TLR2-JNK AXIS

Rinse K. Weersma  et al.

DISRUPTION OF THE GUT MICROBIOME IN RENAL TRANSPLANT RECIPIENTS: RESULTS FROM THE TRANSPLANTLINES COHORT AND BIOBANK STUDY
DISRUPTION OF THE GUT MICROBIOME IN RENAL TRANSPLANT RECIPIENTS: RESULTS FROM THE TRANSPLANTLINES COHORT AND BIOBANK STUDY

Rinse K. Weersma  et al.

HOST-GENETICS, DYSBIOSIS AND CLINICAL HISTORY EXPLAINS FECAL METABOLIC ALTERATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
HOST-GENETICS, DYSBIOSIS AND CLINICAL HISTORY EXPLAINS FECAL METABOLIC ALTERATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE
DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

THE ALTERATION OF GUT MICROBIOME IN LIVER TRANSPLANTATION: FIRST RESULTS FROM THE TRANSPLANTLINES BIOBANK AND COHORT STUDY
THE ALTERATION OF GUT MICROBIOME IN LIVER TRANSPLANTATION: FIRST RESULTS FROM THE TRANSPLANTLINES BIOBANK AND COHORT STUDY

Rinse K. Weersma  et al.

Item 21 - 40 / 45
1
2
3